Key Takeaways
- Noxopharm’s SOF-SKN drug shows a significant skin half-life of 3.5 days with minimal systemic absorption.
- Results aid in refining human dosing frequency and will be included in future regulatory submissions.
- The company faces financial challenges, including increased losses and leadership changes, but has secured additional funding resources.
Preclinical Results Overview
Noxopharm (ASX: NOX) announced positive preclinical results for its SOF-SKN drug candidate, highlighting a significant skin half-life of approximately 3.5 days and minimal systemic absorption. The study, conducted on both normal and disease-like skin, examined the uptake of SOF-16, the active ingredient in SOF-SKN, at the maximum dose from the HERACLES trial. Findings indicated that SOF-16 remained localized in the skin for an extended duration, a crucial development for optimizing the dosing regimen and preparing for upcoming regulatory submissions.
Notably, drug concentration in the dermis was consistent across various skin models, and absorption into the bloodstream was undetectable at all measured intervals. This suggests a highly targeted therapeutic action of SOF-16, confined to the epidermal and dermal layers, which are key areas for treatment.
Dosing Strategy and Regulatory Steps
These findings are significant for the next stages of SOF-SKN’s development. The data assists in determining a suitable dosing frequency for human applications, potentially allowing for less frequent application than daily due to the drug’s prolonged skin retention. Noxopharm is planning to incorporate these important results into the regulatory submission package for the next phase of the drug’s development. Additionally, the company is collaborating with a Contract Research Organisation (CRO) to facilitate preparations for forthcoming human trials.
Leadership Transition and Financial Status
In a related development, Noxopharm announced a leadership change with Dr. Olivier Laczka appointed as the new Chief Executive Officer, starting April 15, 2026. This change followed the resignation of Dr. Gisela Mautner, the previous CEO and Managing Director. Dr. Laczka, who previously held the role of Chief Scientific Officer for Inflammation, played a significant part in advancing the Sofr technology platform.
Noxopharm is also navigating financial challenges, reporting a widening half-year loss for the period ending December 31, 2025, principally driven by ongoing research and operational expenditures. The company’s financial standing has weakened, reflecting increased cash burn and liabilities. To mitigate these challenges, Noxopharm activated an At-the-Market (ATM) facility on February 27, 2026, to access up to $5 million in standby equity and received a rebate of $2,806,583 from the Australian Government’s R&D Tax Incentive scheme for FY2024-25, bolstering its cash position.
Outlook
While Noxopharm’s preclinical data for SOF-SKN presents a promising profile for sustained skin retention with minimal systemic exposure, allowing for potentially less frequent dosing, the company must address ongoing financial pressures and recent leadership transitions as critical factors for investors to consider.
The content above is a summary. For more details, see the source article.